AWM
ESPR

Apollon Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

Apollon Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$9.84K – 1336
2025
Q2 		$9.84K Sell
10,000
-29
-0.3% -$29 ﹤0.01% 1269
2025
Q1 		$14.4K Buy
10,029
+29
+0.3% +$53 ﹤0.01% 1201
2024
Q4 		$22K Hold
10,000
– – ﹤0.01% 1185
2024
Q3 		$16.5K Hold
10,000
– – ﹤0.01% 1126
2024
Q2 		$22.2K Hold
10,000
– – ﹤0.01% 1091
2024
Q1 		$26.8K Buy
+10,000
New +$24.3K ﹤0.01% 1099

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Apollon Wealth Management's ESPR Position: Q3 2025 in Review

Apollon Wealth Management sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 10,000 shares — an estimated $9.84K sold.

Apollon Wealth Management first reported a position in ESPR in Q1 2024 and held it in 6 quarters. The position peaked at $26.8K in Q1 2024. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Apollon Wealth Management reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Apollon Wealth Management sold 10,000 Esperion Therapeutics shares in Q3 2025, an estimated $9.84K.
  • Apollon Wealth Management first reported a position in Esperion Therapeutics in Q1 2024 and held it in 6 quarters.
  • Apollon Wealth Management's Esperion Therapeutics position peaked at $26.8K in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Apollon Wealth Management's 13F filing for Q3 2025, filed 17 Oct 2025.